Keserü M, Green S, Dulz S
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf.
Klin Monbl Augenheilkd. 2017 Jan;234(1):64-69. doi: 10.1055/s-0042-121606. Epub 2017 Jan 30.
Basal cell carcinoma (BCC) is the commonest periorbital tumour. Mohs' micrographic surgery and secondary reconstruction is the therapeutic gold standard for periorbital BCC. In cases of inoperability for any reason, therapeutic alternatives are needed. Since the approval of vismodegib, an orally administered, targeted BCC therapy is available. Nevertheless there is little information on the use of vismodegib for periorbital BCC. In a retrospective study, we analysed the data of 4 patients treated with vismodegib since 2014. The patients' mean age before starting therapy was 87 years. The mean maximum tumour diameter was 22.0 mm. The median follow-up was 17 months. The median treatment duration was 7.5 months. In 75 % of patients, complete clinical remission of BCC was achieved. In 25 % of patients, interim stabilisation of tumour growth was possible. The most common side effect of therapy was muscle spasm. Vismodegib is an effective treatment option for patients with periorbital BCC, in whom surgical treatment is not possible for any reason.
基底细胞癌（BCC）是最常见的眶周肿瘤。莫氏显微外科手术及二期重建是眶周BCC的治疗金标准。对于因任何原因无法进行手术的病例，需要其他治疗选择。自维莫德吉获批以来，一种口服的靶向BCC治疗方法可供使用。然而，关于维莫德吉用于眶周BCC的使用信息很少。在一项回顾性研究中，我们分析了自2014年以来接受维莫德吉治疗的4例患者的数据。开始治疗前患者的平均年龄为87岁。肿瘤最大平均直径为22.0毫米。中位随访时间为17个月。中位治疗持续时间为7.5个月。75%的患者实现了BCC的完全临床缓解。25%的患者实现了肿瘤生长的暂时稳定。治疗最常见的副作用是肌肉痉挛。对于因任何原因无法进行手术治疗的眶周BCC患者，维莫德吉是一种有效的治疗选择。
